Logo

EU Green Lights Apalutamide for Nonmetastatic CRPC

ARTICLES

EU Green Lights Apalutamide for Nonmetastatic CRPC


MEDSCAPE  
PUBLISHED: 16 NOVEMBER 2018


The next-generation oral antiandrogen product apalutamide (Erleada, Janssen), is approaching approval in Europe for use in nonmetastatic castration-resistant prostate cancer (nmCRPC). The product received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency at its last meeting. The positive opinion will now be reviewed by the European Commission, which approves products for use in the European Union.

explore_now-footer.png

Published

November 16, 2018

Categories

Oncology
CP-202103